Clinical Orthopaedics and Related Research®

, Volume 470, Issue 9, pp 2462–2475

Evidence for Using Bisphosphonate to Treat Legg-Calvé-Perthes Disease

  • Megan L. Young
  • David G. Little
  • Harry K. W. Kim
Symposium: Legg-Calvé-Perthes Disease: Where Do We Stand After 100 Years?



The rationale for using bisphosphonate (BP) therapy for Legg-Calvé-Perthes disease (LCPD) is the potential to prevent substantial femoral head deformity during the fragmentation phase by inhibiting osteoclastic bone resorption. However, it is unclear whether BP therapy decreases femoral head deformity.


In this systematic review, we answered the following questions: (1) Does bisphosphonate (BP) therapy decrease femoral head deformity and improve pain and function in LCPD or other juvenile osteonecrotic conditions? And (2) does BP therapy decrease femoral head deformity in experimental studies of juvenile femoral head osteonecrosis?


We searched the literature from 1966 to 2011 for clinical and experimental studies on BP therapy for juvenile femoral head osteonecrosis. Studies specifically addressing clinical and/or radiographic/histologic outcomes pertaining to pain and function and femoral head morphology were analyzed.


Three Level IV clinical studies met our inclusion criteria. Only one study initiated BP therapy during the precollapsed stage of osteonecrosis and reported prevention of femoral head deformity in nine of 17 patients. All studies noted subjective improvements of pain and gait in patients treated with intravenous BPs. Of the eight experimental studies reviewed, seven reported reduced femoral head deformity and six found better preservation of trabecular framework in animals treated with BPs.


Clinical evidence lacks consistent patient groups and drug protocols to draw definitive conclusions that BP therapy can decrease femoral head deformity in juvenile osteonecrotic conditions. Experimental studies suggest BP therapy protects the infarcted femoral head from deformity, but it lacks bone anabolic effect. Further basic and clinical research are required to determine the potential role of BPs as a medical treatment for LCPD.


  1. 1.
    Agarwala S, Jain D, Joshi VR, Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip: a prospective open-label study. Rheumatology (Oxford). 2005;44:352–359.CrossRefGoogle Scholar
  2. 2.
    Agarwala S, Shah S, Joshi VR. The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years. J Bone Joint Surg Br. 2009;91:1013–1018.PubMedCrossRefGoogle Scholar
  3. 3.
    Aya-ay J, Athavale S, Morgan-Bagley S, Bian H, Bauss F, Kim HK. Retention, distribution, and effects of intraosseously administered ibandronate in the infarcted femoral head. J Bone Miner Res. 2007;22:93–100.PubMedCrossRefGoogle Scholar
  4. 4.
    Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagni A, Galbiati E, Corona F, Luisetto G, Giuntini D, Picco P, Brandi ML, Falcini F. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum. 2000;43:1960–1966.PubMedCrossRefGoogle Scholar
  5. 5.
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–1541.Google Scholar
  6. 6.
    Calvé J. Sur une forme particulière de pseudo-coxalgie greffée sur des déformations caractéristiques de l’extrémité supérieure du fémur. Rev Chir. 1910;42:54–84.Google Scholar
  7. 7.
    Camacho NP, Raggio CL, Doty SB, Root L, Zraick V, Ilg WA, Toledano TR, Boskey AL. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int. 2001;69:94–101.PubMedCrossRefGoogle Scholar
  8. 8.
    Canavese F, Dimeglio A. Perthes’ disease: prognosis in children under six years of age. J Bone Joint Surg Br. 2008;90:940–945.PubMedCrossRefGoogle Scholar
  9. 9.
    Catterall A, Pringle J, Byers PD, Fulford GE, Kemp HB, Dolman CL, Bell HM, McKibbin B, Rális Z, Jensen OM, Lauritzen J, Ponseti IV, Ogden J. A review of the morphology of Perthes’ disease. J Bone Joint Surg Br. 1982;64:269–275.PubMedGoogle Scholar
  10. 10.
    Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947–952.PubMedCrossRefGoogle Scholar
  11. 11.
    Herring JA, Kim HT, Browne R. Legg-Calvé-Perthes disease. Part II. Prospective multicenter study of the effect of treatment on outcome. J Bone Joint Surg Am. 2004;86:2121–2134.PubMedGoogle Scholar
  12. 12.
    Hofstaetter JG, Wang J, Yan J, Glimcher MJ. The effects of alendronate in the treatment of experimental osteonecrosis of the hip in adult rabbits. Osteoarthritis Cartilage. 2009;17:362–370.PubMedCrossRefGoogle Scholar
  13. 13.
    Johannesen J, Briody J, McQuade M, Little DG, Cowell CT, Munns CF. Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calvé-Perthes disease. Bone. 2009;45:898–902.PubMedCrossRefGoogle Scholar
  14. 14.
    Jonsater S. Coxa plana: a histo-pathologic and arthrographic study. Acta Orthop Scand Suppl. 1953;12:5–98.PubMedGoogle Scholar
  15. 15.
    Joseph B, Rao N, Mulpuri K, Varghese G, Nair S. How does a femoral varus osteotomy alter the natural evolution of Perthes’ disease? J Pediatr Orthop B. 2005;14:10–15.PubMedCrossRefGoogle Scholar
  16. 16.
    Kim HK, Morgan-Bagley S, Kostenuik P. RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis. J Bone Miner Res. 2006;21:1946–1954.PubMedCrossRefGoogle Scholar
  17. 17.
    Kim HK, Randall TS, Bian H, Jenkins J, Garces A, Bauss F. Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs. J Bone Joint Surg Am. 2005;87:550–557.PubMedCrossRefGoogle Scholar
  18. 18.
    Kim HK, Sanders M, Athavale S, Bian H, Bauss F. Local bioavailability and distribution of systemically (parenterally) administered ibandronate in the infarcted femoral head. Bone. 2006;39:205–212.PubMedCrossRefGoogle Scholar
  19. 19.
    Kim HK, Su PH. Development of flattening and apparent fragmentation following ischemic necrosis of the capital femoral epiphysis in a piglet model. J Bone Joint Surg Am. 2002;84:1329–1334.PubMedGoogle Scholar
  20. 20.
    Koob TJ, Pringle D, Gedbaw E, Meredith J, Berrios R, Kim HK. Biomechanical properties of bone and cartilage in growing femoral head following ischemic osteonecrosis. J Orthop Res. 2007;25:750–757.PubMedCrossRefGoogle Scholar
  21. 21.
    Kotecha RS, Powers N, Lee SJ, Murray KJ, Carter T, Cole C. Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL). Pediatr Blood Cancer. 2010;54:934–940.PubMedGoogle Scholar
  22. 22.
    Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis: a randomized clinical study. J Bone Joint Surg Am. 2005;87:2155–2159.PubMedCrossRefGoogle Scholar
  23. 23.
    Lala R, Matarazzo P, Andreo M, Marzari D, Bellone J, Corrias A, de Sanctis C. Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2006;19(suppl 2):583–593.PubMedCrossRefGoogle Scholar
  24. 24.
    Legg AT. An obscure affection of the hip joint. Boston Med Surg J. 1910;162:202–204.CrossRefGoogle Scholar
  25. 25.
    Lepola VT, Hannuniemi R, Kippo K, Lauren L, Jalovaara P, Vaananen HK. Long-term effects of clodronate on growing rat bone. Bone. 1996;18:191–196.PubMedCrossRefGoogle Scholar
  26. 26.
    Li C, Mori S, Li J, Kaji Y, Akiyama T, Kawanishi J, Norimatsu H. Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res. 2001;16:429–436.PubMedCrossRefGoogle Scholar
  27. 27.
    Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437–1443.PubMedCrossRefGoogle Scholar
  28. 28.
    Little DG, McDonald M, Sharpe IT, Peat R, Williams P, McEvoy T. Zoledronic acid improves femoral head sphericity in a rat model of Perthes disease. J Orthop Res. 2005;23:862–868.PubMedCrossRefGoogle Scholar
  29. 29.
    Little DG, Peat RA, McEvoy A, Williams PR, Smith EJ, Baldock PA. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J Bone Miner Res. 2003;18:2016–2022.PubMedCrossRefGoogle Scholar
  30. 30.
    Lteif AN, Zimmerman D. Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics. 1998;102(4 pt 1):990–993.PubMedCrossRefGoogle Scholar
  31. 31.
    McQuade M, Houghton K. Use of bisphosphonates in a case of Perthes disease. Orthop Nurs. 2005;24:393–398.PubMedCrossRefGoogle Scholar
  32. 32.
    Nguyen T, Zacharin MR. Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia—two-year outcomes. J Pediatr Endocrinol Metab. 2006;19:161–167.PubMedCrossRefGoogle Scholar
  33. 33.
    Nishii T, Sugano N, Miki H, Hashimoto J, Yoshikawa H. Does alendronate prevent collapse in osteonecrosis of the femoral head? Clin Orthop Relat Res. 2006;443:273–279.PubMedCrossRefGoogle Scholar
  34. 34.
    Peled E, Bejar J, Zinman C, Boss JH, Reis DN, Norman D. Prevention of distortion of vascular deprivation-induced osteonecrosis of the rat femoral head by treatment with alendronate. Arch Orthop Trauma Surg. 2009;129:275–279.PubMedCrossRefGoogle Scholar
  35. 35.
    Peled E, Bejar J, Zinman C, Reis DN, Boss JH, Ben-Noon H, Norman D. Alendronate preserves femoral head shape and height/length ratios in an experimental rat model: a computer-assisted analysis. Indian J Orthop. 2009;43:22–26.PubMedCrossRefGoogle Scholar
  36. 36.
    Perthes G. Über arthritis deformans juvenilis. Deutsche Zeitschr Chir. 1910;107:111–159.CrossRefGoogle Scholar
  37. 37.
    Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2008;4:CD005088.Google Scholar
  38. 38.
    Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab. 2003;88:4569–4575.PubMedCrossRefGoogle Scholar
  39. 39.
    Pringle D, Koob TJ, Kim HK. Indentation properties of growing femoral head following ischemic necrosis. J Orthop Res. 2004;22:122–130.PubMedCrossRefGoogle Scholar
  40. 40.
    Ramachandran M, Ward K, Brown RR, Munns CF, Cowell CT, Little DG. Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. J Bone Joint Surg Am. 2007;89:1727–1734.PubMedCrossRefGoogle Scholar
  41. 41.
    Reid IR, Nicholson GC, Weinstein RS, Hosking DJ, Cundy T, Kotowicz MA, Murphy WA Jr, Yeap S, Dufresne S, Lombardi A, Musliner TA, Thompson DE, Yates AJ. Biochemical and radiologic improvement in Paget’s disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med. 1996;101:341–348.PubMedCrossRefGoogle Scholar
  42. 42.
    Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735–1744.PubMedCrossRefGoogle Scholar
  43. 43.
    Rosenfeld SB, Herring JA, Chao JC. Legg-Calvé-Perthes disease: a review of cases with onset before six years of age. J Bone Joint Surg Am. 2007;89:2712–2722.PubMedCrossRefGoogle Scholar
  44. 44.
    Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712–716.PubMedCrossRefGoogle Scholar
  45. 45.
    Vandermeer JS, Kamiya N, Aya-ay J, Garces A, Browne R, Kim HK. Local administration of ibandronate and bone morphogenetic protein-2 after ischemic osteonecrosis of the immature femoral head: a combined therapy that stimulates bone formation and decreases femoral head deformity. J Bone Joint Surg Am. 2011;93:905–913.PubMedCrossRefGoogle Scholar
  46. 46.
    Ward LM, Rauch F, Whyte MP, D’Astous J, Gates PE, Grogan D, Lester EL, McCall RE, Pressly TA, Sanders JO, Smith PA, Steiner RD, Sullivan E, Tyerman G, Smith-Wright DL, Verbruggen N, Heyden N, Lombardi A, Glorieux FH. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab. 2011;96:355–364.PubMedCrossRefGoogle Scholar
  47. 47.
    Wiig O, Terjesen T, Svenningsen S. Prognostic factors and outcome of treatment in Perthes’ disease: a prospective study of 368 patients with five-year follow-up. J Bone Joint Surg Br. 2008;90:1364–1371.PubMedCrossRefGoogle Scholar
  48. 48.
    Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics. 2003;111(5 pt 1):1030–1036.PubMedCrossRefGoogle Scholar

Copyright information

© The Association of Bone and Joint Surgeons® 2012

Authors and Affiliations

  • Megan L. Young
    • 1
  • David G. Little
    • 2
  • Harry K. W. Kim
    • 3
  1. 1.Texas Scottish Rite Hospital for Children, UT Southwestern Medical CenterDallasUSA
  2. 2.Department of Orthopaedic Research and BiotechnologyThe Children’s Hospital at WestmeadWestmeadAustralia
  3. 3.Center for Excellence in Hip DisordersTexas Scottish Rite Hospital for Children, UT Southwestern Medical CenterDallasUSA

Personalised recommendations